Full history for every metric is available with a Kvantra account
PHAXIAM Therapeutics S.A. (PHXM.PA)
Key financial summary
Financials in EUR| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 5 | 4 | 4 | 7 | 1 | 2 |
| Operating profit | €m | -24 | -22 | |||||
| Net profit | €m | -38 | -63 | -73 | -54 | -0 | -23 | -22 |
| EPS reported | € | -5.00 | -3.94 | |||||
| Operating cashflow per share | € | -5.20 | -5.20 | |||||
| Capex per share | € | 0.05 | 0.05 | |||||
| FCF per share | € | -5.25 | -5.25 | |||||
| Free cash flow | €m | -25 | -21 | |||||
| Net debt | €m | -0 | 9 | |||||
| Book value equity | €m | 26 | 15 | |||||
| Book value per share | € | 5.46 | 2.54 | |||||
| Number of shares | m | 4.7 | 6.07 | |||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.78 | 0.07 | |||||
| P/S LTM | x | 15.05 | 0.47 | |||||
| P/FCF LTM | x | -0.81 | -0.05 | |||||
| EV/EBITDA LTM | x | -0.99 | -0.59 | |||||
| EV/Sales LTM | x | 17.15 | 4.87 | |||||
| Earnings Yield LTM | % | -117.71% | -4977.7% | |||||
| FCF Yield | % | -123.51% | -2127.2% | |||||
| Quality | ||||||||
| ROE | % | -91.71% | -95.68% | |||||
| ROIC | % | -56.27% | -56.27% | |||||
| Operating margin | % | -1784.3% | -1784.3% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -1858.6% | -1858.6% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -80.05% | -64.15% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.86 | -1.98 | |||||
| Net Debt/EBITDA | x | -0.12 | -0.12 | |||||
| EBIT/Net interest | x | -120.71 | -120.71 | |||||
| Net debt/market cap | % | -1.38% | 931.23% | |||||
| Net debt/Equity | x | -0.01 | 0.61 | |||||
| Gross debt/equity | x | 0.52 | 0.70 | |||||
Company overview
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
PHAXIAM Therapeutics S.A. (PHXM.PA)
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free